Ratings Thermo Fisher Scientific Inc. Buenos Aires S.E.

Equities

TMO

ARBCOM4601F7

End-of-day quote Buenos Aires S.E. Other stock markets 23:00:00 16/05/2024 BST			5-day change	1st Jan Change
29,616 ^ARS	-0.89%		+2.12%	+26.60%

05-15	Thermo Fisher Scientific Introduces Array-Based Solution for Extended Blood Type Research to Support Future Advancements Toward Safer Transfusions	CI
05-14	Transcript : Thermo Fisher Scientific Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 08:00 AM

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The company returns high margins, thereby supporting business profitability.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The group shows a rather high level of debt in proportion to its EBITDA.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 37.46 times its estimated earnings per share for the ongoing year.
The company's "enterprise value to sales" ratio is among the highest in the world.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The company is highly valued given the cash flows generated by its activity.
The company is not the most generous with respect to shareholders' compensation.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
For the past year, analysts have significantly revised downwards their profit estimates.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
THERMO FISHER SCIENTIFIC INC.	+26.60%	227B	-
DANAHER CORPORATION	+14.90%	197B	B-
INTUITIVE SURGICAL, INC.	+18.22%	141B	B-
BOSTON SCIENTIFIC CORPORATION	+29.15%	110B	A-
SIEMENS HEALTHINEERS AG	+0.53%	64.15B	A-
EDWARDS LIFESCIENCES CORPORATION	+16.92%	53.72B	B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+6.33%	51.75B	B+
AGILENT TECHNOLOGIES, INC.	+10.93%	45.2B	A
GE HEALTHCARE TECHNOLOGIES INC.	+5.87%	37.37B	-
RESMED, INC.	+27.06%	32.11B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes